These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 29310667

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury.
    Tchantchou F, Zhang Y.
    J Neurotrauma; 2013 Apr 01; 30(7):565-79. PubMed ID: 23151067
    [Abstract] [Full Text] [Related]

  • 5. The α/β-hydrolase domain 6 inhibitor WWL70 decreases endotoxin-induced lung inflammation in mice, potential contribution of 2-arachidonoylglycerol, and lysoglycerophospholipids.
    Bottemanne P, Paquot A, Ameraoui H, Alhouayek M, Muccioli GG.
    FASEB J; 2019 Jun 01; 33(6):7635-7646. PubMed ID: 30896979
    [Abstract] [Full Text] [Related]

  • 6. Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
    Ignatowska-Jankowska B, Wilkerson JL, Mustafa M, Abdullah R, Niphakis M, Wiley JL, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2015 May 01; 353(2):424-32. PubMed ID: 25762694
    [Abstract] [Full Text] [Related]

  • 7. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
    Wilkerson JL, Niphakis MJ, Grim TW, Mustafa MA, Abdullah RA, Poklis JL, Dewey WL, Akbarali H, Banks ML, Wise LE, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2016 Apr 01; 357(1):145-56. PubMed ID: 26791602
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.
    Crowe MS, Leishman E, Banks ML, Gujjar R, Mahadevan A, Bradshaw HB, Kinsey SG.
    Br J Pharmacol; 2015 Apr 01; 172(7):1700-12. PubMed ID: 25393148
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Wilkerson JL, Ghosh S, Mustafa M, Abdullah RA, Niphakis MJ, Cabrera R, Maldonado RL, Cravatt BF, Lichtman AH.
    Neuropharmacology; 2017 Mar 01; 114():156-167. PubMed ID: 27890602
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic Effect of the Substrate-Selective COX-2 Inhibitor IMMA in the Animal Model of Chronic Constriction Injury.
    Jones M, Wen J, Selvaraj P, Tanaka M, Moran S, Zhang Y.
    Front Pharmacol; 2018 Mar 01; 9():1481. PubMed ID: 30618769
    [Abstract] [Full Text] [Related]

  • 13. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
    Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2015 Aug 01; 354(2):111-20. PubMed ID: 25998048
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis.
    Manterola A, Bernal-Chico A, Cipriani R, Ruiz A, Pérez-Samartín A, Moreno-Rodríguez M, Hsu KL, Cravatt BF, Brown JM, Rodríguez-Puertas R, Matute C, Mato S.
    Neuropharmacology; 2018 Oct 01; 141():181-191. PubMed ID: 30171986
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.
    Owens RA, Mustafa MA, Ignatowska-Jankowska BM, Damaj MI, Beardsley PM, Wiley JL, Niphakis MJ, Cravatt BF, Lichtman AH.
    Neuropharmacology; 2017 Oct 01; 125():80-86. PubMed ID: 28673548
    [Abstract] [Full Text] [Related]

  • 18. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.
    Kinsey SG, Long JZ, Cravatt BF, Lichtman AH.
    J Pain; 2010 Dec 01; 11(12):1420-8. PubMed ID: 20554481
    [Abstract] [Full Text] [Related]

  • 19. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
    Adamson Barnes NS, Mitchell VA, Kazantzis NP, Vaughan CW.
    Br J Pharmacol; 2016 Jan 01; 173(1):77-87. PubMed ID: 26398331
    [Abstract] [Full Text] [Related]

  • 20. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.
    Pasquarelli N, Porazik C, Hanselmann J, Weydt P, Ferger B, Witting A.
    Neuropharmacology; 2015 Apr 01; 91():148-56. PubMed ID: 25497453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.